Repligen (NASDAQ:RGEN) Now Covered by Analysts at TD Cowen

TD Cowen initiated coverage on shares of Repligen (NASDAQ:RGEN) in a research report sent to investors on Monday, MarketBeat Ratings reports. The firm issued a buy rating and a $200.00 price target on the biotechnology company’s stock.

RGEN has been the subject of a number of other reports. HC Wainwright cut their price objective on Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd. Wolfe Research assumed coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Finally, Canaccord Genuity Group assumed coverage on Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Six research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and an average target price of $186.00.

Repligen Trading Down 1.4 %

Shares of Repligen stock opened at $153.86 on Monday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock has a market capitalization of $8.62 billion, a PE ratio of -415.83, a P/E/G ratio of 4.54 and a beta of 0.99. Repligen has a 1-year low of $113.50 and a 1-year high of $211.13. The company’s fifty day simple moving average is $155.37 and its 200-day simple moving average is $148.93.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same quarter in the previous year, the company posted $0.23 earnings per share. Repligen’s revenue for the quarter was up 9.7% on a year-over-year basis. As a group, equities analysts anticipate that Repligen will post 1.54 earnings per share for the current year.

Hedge Funds Weigh In On Repligen

A number of institutional investors and hedge funds have recently modified their holdings of RGEN. Signaturefd LLC boosted its stake in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after buying an additional 124 shares during the period. UMB Bank n.a. boosted its stake in shares of Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the period. Blue Trust Inc. grew its holdings in Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 127 shares during the last quarter. Resources Management Corp CT ADV purchased a new stake in Repligen in the 3rd quarter worth about $37,000. Finally, Quarry LP lifted its stake in Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 239 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.